SYDNEY, May 8, 2019
/PRNewswire/ -- This World Ovarian Cancer Day, Australian
oncology-focused biotech company Kazia Therapeutics Ltd (ASX: KZA,
NASDAQ: KZIA) calls for greater awareness of what is the most
lethal gynaecological cancer in the US.
In 2019, around 22,530 women will receive a new diagnosis of
ovarian cancer[1] while the disease has one of the
lowest survival rates of all female cancers, with only 46.5% of
patients surviving five years post diagnosis[2].
Kazia's CEO, Dr James Garner
said, "In 2019, more than 13,000 women will die from ovarian cancer
in the US, so we are urging all women to understand all of the
major signs and symptoms of ovarian cancer and seek regular
check-ups with their doctors if feeling unwell.
The four major symptoms of ovarian cancer are feeling full after
eating a small amount, increased abdominal size or persistent
bloating, abdominal or pelvic pain and the need to urinate urgently
or often. Given these are symptoms common to other easily explained
conditions means that patients present for diagnosis late."
The most commonly reported symptoms are[3]:
- Bloating
- Pelvic or abdominal (belly) pain
- Trouble eating or feeling full quickly
- Urinary symptoms such as urgency (always feeling like you have
to go) or frequency (having to go often)
Other signs to watch out for include[4]:
- Fatigue (extreme tiredness)
- Upset stomach
- Back pain
- Pain during sex
- Constipation
- Changes in a woman's period, such as heavier bleeding than
normal or irregular bleeding
- Abdominal (belly) swelling with weight loss
Sally Goers Fox was diagnosed
with ovarian cancer in 2005. She was misdiagnosed twice by
gynaecologists before her family doctor diagnosed her and she went
on to be treated successfully. She says, looking back, she had
ovarian cancer symptoms for around 18 months.
"There needs to be much more education about it. I am
well-educated, well read and I am an 'on top of my medical stuff
kind of person'. I also had breast cancer at an early age … so I
was on high alert. I didn't know that I had a lot of the classic
symptoms for ovarian cancer. I just didn't know.
"[My advice to women is] to dig deeper in terms of learning
about the symptoms. If you want to arm yourself in the best way,
learn a lot more about the symptoms than just the typical list that
you get."
Kazia Therapeutics is developing a treatment called Cantrixil
for ovarian cancer, which is currently in phase I human trials in
hospitals across Australia and
the United States.
The Company recently reported early efficacy results from Part A
of the phase I study. Of nine patients evaluable for efficacy, five
(56%) achieved stable disease after two cycles of Cantrixil
monotherapy. One of these five patients subsequently achieved a
partial response when Cantrixil was administered with chemotherapy,
as intended per protocol.
Cantrixil may provide a new treatment option for women with
later-stage ovarian cancer, who received limited benefit from
existing chemotherapy. Depending on clinical trial results,
Cantrixil could prolong survival rates for women with ovarian
cancer by targeting chemotherapy-resistant tumour-initiating cells
that are thought to be responsible for disease relapse.
For more information on Kazia Therapeutics or Cantrixil, please
visit: www.kaziatherapeutics.com
[1] Source: American Cancer Society:
https://www.cancer.org/cancer/ovarian-cancer/about/key-statistics.html
[2] Source: Ovarian Cancer Research
Alliance:
https://ocrahope.org/patients/about-ovarian-cancer/statistics/
[3] Source: American Cancer Society:
https://www.cancer.org/cancer/ovarian-cancer/detection-diagnosis-staging/signs-and-symptoms.html.
[4] Source: American Cancer Society:
https://www.cancer.org/cancer/ovarian-cancer/detection-diagnosis-staging/signs-and-symptoms.html.
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/kazia-calls-for-greater-awareness-of-the-deadliest-gynecological-cancer-in-the-us-300846138.html
SOURCE Kazia Therapeutics Limited